{
  "index": 331,
  "prompt": "\nGiven the following scenario, first consider the actors and stakeholders involved then extrapolate and present as a timeline how the situation might evolve. \nConsider as many multiple possibilities based on possible responses which are to be represented as branches on this timeline. \n\nMake sure that the timeline generated are of **HIGH QUALITY** as defined by the following criteria\n* Plausibility: Economic, financial and political plausibility of each path on the timeline \n    * High: Events are strongly supported by current macro data, institutional knowledge, and have strong analogs in history or system models (e.g., “monetary tightening leads to recession, triggering a political backlash”)\n    * Low: Contains major violations of cause-effect logic, timing, or real-world behavior (e.g., hyperinflation causes interest rate cuts during a currency collapse)\n* Novelty: Creativity/originality in the nodes and paths, are they something you may have overlooked?\n    * High: Demonstrates expert-level creative reasoning. Identifies counterintuitive paths, rare risks, or hidden feedback loops. May challenge conventional wisdom in a grounded way (e.g., “trade war accelerates global realignment of semiconductors via Middle East sovereign wealth capital”). Could lead to edge in investment or policy thinking.\n    * Low: Timeline is linear, obvious, or closely tracks past headlines or boilerplate analysis. No creative branching or exploration.\n* Elaboration: How specific and refined are the occurrences represented by the nodes?\n    * High: Timeline reads like a mini-case study. Each node could stand alone as an actionable insight. Paths show feedback loops, strategic responses, and sector-level granularity (e.g., “Volkswagen reallocates $1.2B R&D from EVs to hybrid tech in response to rare earth prices”). Truly investment-grade thinking.\n    * Low: Nodes are generic (e.g., “market reacts”, “tensions rise”) with no detail on mechanisms, actors, or consequences. Lacks causal clarity.\n* Actionable: Can this timeline inform specific investment actions or hedging strategies?\n    * High: Timeline includes sector impacts, asset class consequences, or opportunities (e.g., “short EU auto suppliers”, “long U.S. rail freight”)\n    * Low: Insightful narrative, but no clear link to tradable instruments or positioning ideas\n\nKeep to the output format below where ascii is used to represent the timeline as a tree. \n\n[Example of Scenario]\nWASHINGTON/DETROIT, April 29 (Reuters) - U.S. President Donald Trump signed a pair of orders to soften the blow of his auto tariffs on Tuesday with a mix of credits and relief from other levies on materials, and his trade team touted its first deal with a foreign trading partner.\nThe developments helped eased some investor worries about the erratic trade policies of Trump as the president visited Michigan, a cradle of the U.S. auto industry, just days before a fresh set of 25% import taxes was set to kick in on automotive components.\n\n[Example of Output]\n{\n  \"id\": \"T0\",\n  \"title\": \"Initial Event\",\n  \"description\": \"German inflation data released at 2.2%\",\n  \"children\": [\n    {\n      \"id\": \"T1A1\",\n      \"title\": \"ECB maintains dovish stance\",\n      \"date_range\": \"May\",\n      \"description\": \"ECB maintains dovish stance, keeps rates low\",\n      \"children\": [\n        {\n          \"id\": \"T1A1.1\",\n          \"title\": \"German banks increase lending\",\n          \"description\": \"German banks benefit from low rates, increase lending\"\n        },\n        {\n          \"id\": \"T1A1.2\",\n          \"title\": \"Euro weakens\",\n          \"description\": \"Euro weakens, boosting exports\"\n        },\n        {\n          \"id\": \"T1A1.3\",\n          \"title\": \"Moderate industrial growth\",\n          \"description\": \"German industry reports moderate growth\"\n        },\n        {\n          \"id\": \"T1A1.4\",\n          \"title\": \"Bundesbank caution\",\n          \"description\": \"Bundesbank signals caution on inflation\",\n          \"children\": [\n            {\n              \"id\": \"T2A1\",\n              \"title\": \"Industry adapts to inflation\",\n              \"date_range\": \"June–August\",\n              \"description\": \"Companies pass on higher costs; unions request wage hikes; consumer shifts emerge\",\n              \"children\": [\n                {\n                  \"id\": \"T3A1\",\n                  \"title\": \"Markets stabilize\",\n                  \"date_range\": \"Q3–Q4\",\n                  \"description\": \"Eurozone growth outlook improves; German stocks outperform\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4A1\",\n                      \"title\": \"Global growth stabilizes\",\n                      \"date_range\": \"Q4–2025\",\n                      \"description\": \"Global trade rebounds; emerging markets benefit\",\n                      \"children\": [\n                        {\n                          \"id\": \"T5A1\",\n                          \"title\": \"New normal\",\n                          \"date_range\": \"2025+\",\n                          \"description\": \"Stable growth across EU/US; ECB remains dovish\"\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    },\n    {\n      \"id\": \"T1A2\",\n      \"title\": \"ECB tightens monetary policy\",\n      \"date_range\": \"May\",\n      \"description\": \"ECB tightens policy in response to inflation\",\n      \"children\": [\n        {\n          \"id\": \"T1A2.1\",\n          \"title\": \"Euro strengthens\",\n          \"description\": \"Euro strengthens, hurting exports\"\n        },\n        {\n          \"id\": \"T1A2.2\",\n          \"title\": \"Industrial slowdown\",\n          \"description\": \"German industry reports slower growth\"\n        },\n        {\n          \"id\": \"T1A2.3\",\n          \"title\": \"Bundesbank warns\",\n          \"description\": \"Bundesbank warns of inflation risks\"\n        },\n        {\n          \"id\": \"T1A2.4\",\n          \"title\": \"Consumers cut back\",\n          \"description\": \"German consumers cut back on spending\",\n          \"children\": [\n            {\n              \"id\": \"T2A2\",\n              \"title\": \"Industry opposes ECB policy\",\n              \"date_range\": \"June–August\",\n              \"description\": \"Job cuts, political backlash, delayed consumption\",\n              \"children\": [\n                {\n                  \"id\": \"T3A2\",\n                  \"title\": \"Markets unstable\",\n                  \"date_range\": \"Q3–Q4\",\n                  \"description\": \"Growth outlook declines; ECB remains hawkish\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4A2\",\n                      \"title\": \"Global recession risk rises\",\n                      \"date_range\": \"Q4–2025\",\n                      \"description\": \"Trade slows; emerging markets struggle\",\n                      \"children\": [\n                        {\n                          \"id\": \"T5A2\",\n                          \"title\": \"Global downturn\",\n                          \"date_range\": \"2025+\",\n                          \"description\": \"Recession conditions persist; ECB maintains rate hikes\"\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    }\n  ]\n}\n\n[Given Scenario]\nThe global immunotoxins market size was estimated at USD 142.2 million in 2023 and is projected to reach USD 344.7 million by 2034, reflecting a compound annual growth rate (CAGR) of 8.11% during the forecast period of 2024 to 2034. This growth is attributed to the rising global prevalence of various malignancies, increased research and development (R&D) activities, heightened investment and funding, the approval of new immunotoxin therapies, and an increase in collaborations and partnerships. \n\nThe Diphtheria Toxin (DT) segment emerged as the highest revenue-generating segment in the global immunotoxins market in 2023, due to the proven effectiveness of DT-based immunotoxins in targeted cancer therapies. The Pseudomonas Exotoxin segment is anticipated to witness the fastest CAGR during the forecast period, driven by the success of Pseudomonas exotoxin-based therapies in clinical trials and advancements that enhance tumor-targeting capabilities while reducing immunogenicity.\n\nThe therapy development segment accounted for the highest revenue in the global immunotoxins market in 2023, resulting from an increased focus on creating novel immunotoxin-based therapies, substantial investments in research and clinical trials, and a rising demand for targeted cancer treatments. The biomedical research segment is projected to grow at the fastest CAGR during the forecast period, spurred by escalating interest in exploring immunotoxins for new therapeutic applications, increased cancer research funding, and advancements in biotechnology.\n\nNorth America is anticipated to have the highest revenue share during the forecast period, due to the presence of major pharmaceutical and biotechnology companies, advanced healthcare infrastructure, high investment in cancer research, and early adoption of innovative immunotoxin therapies. The Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period, driven by the rising prevalence of cancer, increasing healthcare expenditure, growing biotechnology and pharmaceutical sectors, expanding clinical trial activities, and improvements in healthcare infrastructure.\n\nKey players in the immunotoxins market include Amgen Inc., Eisai Co. Ltd., Genentech (Roche), AbbVie Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Novartis AG, Merck & Co. Inc., Celltech Pharma Ltd., ImmunoGen Inc., BioNTech SE, Macrogenics Inc., Cellerant Therapeutics Inc., Iovance Biotherapeutics Inc., and Zymeworks Inc.\n[Output in JSON]\n",
  "response": "```json\n{\n  \"id\": \"T0\",\n  \"title\": \"Initial Market Conditions\",\n  \"description\": \"The global immunotoxins market is projected to grow at a CAGR of 8.11% from 2024 to 2034, driven by rising cancer prevalence, increased R&D, and new therapy approvals.\",\n  \"children\": [\n    {\n      \"id\": \"T1A1\",\n      \"title\": \"Increased R&D and Funding\",\n      \"date_range\": \"2024-2025\",\n      \"description\": \"Heightened investment and funding in immunotoxin research and development, leading to new therapy approvals and collaborations.\",\n      \"children\": [\n        {\n          \"id\": \"T1A1.1\",\n          \"title\": \"New Therapy Approvals\",\n          \"description\": \"Several new immunotoxin therapies receive regulatory approval, boosting market growth.\"\n        },\n        {\n          \"id\": \"T1A1.2\",\n          \"title\": \"Increased Collaborations\",\n          \"description\": \"Key players form strategic partnerships and collaborations to accelerate therapy development.\"\n        },\n        {\n          \"id\": \"T1A1.3\",\n          \"title\": \"Biomedical Research Surge\",\n          \"description\": \"Escalating interest in exploring immunotoxins for new therapeutic applications, driven by increased cancer research funding.\",\n          \"children\": [\n            {\n              \"id\": \"T2A1\",\n              \"title\": \"Breakthrough Discoveries\",\n              \"date_range\": \"2026-2027\",\n              \"description\": \"Significant breakthroughs in immunotoxin research, leading to more effective and targeted cancer treatments.\",\n              \"children\": [\n                {\n                  \"id\": \"T3A1\",\n                  \"title\": \"Market Expansion\",\n                  \"date_range\": \"2028-2030\",\n                  \"description\": \"Rapid market expansion as new therapies hit the market, driving revenue growth.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4A1\",\n                      \"title\": \"Global Market Leadership\",\n                      \"date_range\": \"2031-2034\",\n                      \"description\": \"North America maintains market leadership, while Asia Pacific sees rapid growth due to increasing healthcare expenditure and clinical trial activities.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T5A1\",\n                          \"title\": \"Sustained Growth\",\n                          \"date_range\": \"2034+\",\n                          \"description\": \"Sustained market growth driven by continuous innovation and increasing adoption of immunotoxin therapies.\"\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    },\n    {\n      \"id\": \"T1A2\",\n      \"title\": \"Regulatory Challenges\",\n      \"date_range\": \"2024-2025\",\n      \"description\": \"Regulatory hurdles and delays in therapy approvals slow down market growth.\",\n      \"children\": [\n        {\n          \"id\": \"T1A2.1\",\n          \"title\": \"Delayed Approvals\",\n          \"description\": \"Several promising immunotoxin therapies face regulatory delays, impacting market growth.\"\n        },\n        {\n          \"id\": \"T1A2.2\",\n          \"title\": \"Increased Scrutiny\",\n          \"description\": \"Regulatory bodies increase scrutiny on immunotoxin therapies, leading to stricter approval criteria.\"\n        },\n        {\n          \"id\": \"T1A2.3\",\n          \"title\": \"Investor Caution\",\n          \"description\": \"Investors become cautious due to regulatory uncertainties, leading to reduced funding for R&D.\",\n          \"children\": [\n            {\n              \"id\": \"T2A2\",\n              \"title\": \"Market Slowdown\",\n              \"date_range\": \"2026-2027\",\n              \"description\": \"Market growth slows down as new therapies face regulatory hurdles and reduced funding.\",\n              \"children\": [\n                {\n                  \"id\": \"T3A2\",\n                  \"title\": \"Innovation Stagnation\",\n                  \"date_range\": \"2028-2030\",\n                  \"description\": \"Innovation stalls due to lack of funding and regulatory challenges, leading to a stagnant market.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4A2\",\n                      \"title\": \"Market Consolidation\",\n                      \"date_range\": \"2031-2034\",\n                      \"description\": \"Key players consolidate market share through acquisitions and partnerships, but overall market growth remains slow.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T5A2\",\n                          \"title\": \"Stagnant Growth\",\n                          \"date_range\": \"2034+\",\n                          \"description\": \"Market growth remains stagnant due to regulatory challenges and lack of innovation.\"\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    },\n    {\n      \"id\": \"T1A3\",\n      \"title\": \"Technological Advancements\",\n      \"date_range\": \"2024-2025\",\n      \"description\": \"Rapid advancements in biotechnology and immunotherapy technologies accelerate market growth.\",\n      \"children\": [\n        {\n          \"id\": \"T1A3.1\",\n          \"title\": \"Enhanced Tumor-Targeting\",\n          \"description\": \"Advancements in tumor-targeting capabilities of immunotoxins, reducing immunogenicity and improving efficacy.\"\n        },\n        {\n          \"id\": \"T1A3.2\",\n          \"title\": \"Increased Clinical Trials\",\n          \"description\": \"More clinical trials for immunotoxin therapies, leading to faster approvals and market entry.\"\n        },\n        {\n          \"id\": \"T1A3.3\",\n          \"title\": \"Biomedical Research Surge\",\n          \"description\": \"Escalating interest in exploring immunotoxins for new therapeutic applications, driven by increased cancer research funding.\",\n          \"children\": [\n            {\n              \"id\": \"T2A3\",\n              \"title\": \"Breakthrough Discoveries\",\n              \"date_range\": \"2026-2027\",\n              \"description\": \"Significant breakthroughs in immunotoxin research, leading to more effective and targeted cancer treatments.\",\n              \"children\": [\n                {\n                  \"id\": \"T3A3\",\n                  \"title\": \"Market Expansion\",\n                  \"date_range\": \"2028-2030\",\n                  \"description\": \"Rapid market expansion as new therapies hit the market, driving revenue growth.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4A3\",\n                      \"title\": \"Global Market Leadership\",\n                      \"date_range\": \"2031-2034\",\n                      \"description\": \"North America maintains market leadership, while Asia Pacific sees rapid growth due to increasing healthcare expenditure and clinical trial activities.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T5A3\",\n                          \"title\": \"Sustained Growth\",\n                          \"date_range\": \"2034+\",\n                          \"description\": \"Sustained market growth driven by continuous innovation and increasing adoption of immunotoxin therapies.\"\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    },\n    {\n      \"id\": \"T1A4\",\n      \"title\": \"Geopolitical Tensions\",\n      \"date_range\": \"2024-2025\",\n      \"description\": \"Geopolitical tensions and trade disputes impact the global immunotoxins market.\",\n      \"children\": [\n        {\n          \"id\": \"T1A4.1\",\n          \"title\": \"Supply Chain Disruptions\",\n          \"description\": \"Geopolitical tensions lead to supply chain disruptions, affecting the availability of raw materials and components.\"\n        },\n        {\n          \"id\": \"T1A4.2\",\n          \"title\": \"Trade Barriers\",\n          \"description\": \"Trade disputes result in tariffs and trade barriers, increasing the cost of immunotoxin therapies.\"\n        },\n        {\n          \"id\": \"T1A4.3\",\n          \"title\": \"Market Fragmentation\",\n          \"description\": \"Geopolitical tensions lead to market fragmentation, with regional markets developing independently.\",\n          \"children\": [\n            {\n              \"id\": \"T2A4\",\n              \"title\": \"Regional Market Growth\",\n              \"date_range\": \"2026-2027\",\n              \"description\": \"Regional markets grow independently, with Asia Pacific and North America leading the way.\",\n              \"children\": [\n                {\n                  \"id\": \"T3A4\",\n                  \"title\": \"Market Diversification\",\n                  \"date_range\": \"2028-2030\",\n                  \"description\": \"Market diversification as companies focus on regional markets, leading to varied growth rates.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4A4\",\n                      \"title\": \"Global Market Fragmentation\",\n                      \"date_range\": \"2031-2034\",\n                      \"description\": \"Global market remains fragmented, with regional leaders emerging in different markets.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T5A4\",\n                          \"title\": \"Fragmented Growth\",\n                          \"date_range\": \"2034+\",\n                          \"description\": \"Fragmented market growth driven by regional dynamics and geopolitical tensions.\"\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    }\n  ]\n}\n```"
}